Question 1

What does Natco Pharma Ltd. look like financially right now?

Accepted Answer

Natco Pharma Ltd. is currently shown with a market value of ₹17.70K Cr. In FY25, reported sales were ₹4.43K Cr and net profit was ₹1.88K Cr. That gives investors a quick starting point: first check whether growth, margins, and cash flow are moving in the same direction before judging the stock only by price.

Question 2

Is Natco Pharma Ltd. growing sales and profit consistently?

Accepted Answer

Natco Pharma Ltd.'s latest annual sales growth is 10.77%, while net profit growth is 35.66%. When sales and profit grow together, quality of growth is usually better. If profit growth trails sales growth, it is worth checking margins, employee cost, finance cost, and tax rate in the P&L tab.

Question 3

How did Natco Pharma Ltd. perform in the latest quarter?

Accepted Answer

For December 2025 quarter, the available quarterly data shows sales of ₹647.30 Cr and net profit of ₹140.40 Cr. A single quarter should not be read in isolation; compare it with the previous quarter and the same quarter last year to separate seasonal movement from a real trend change.

Question 4

Are Natco Pharma Ltd.'s margins healthy?

Accepted Answer

Natco Pharma Ltd.'s latest operating margin is 53.31%, and net profit margin is 39.37%. That points to a business with reasonable profit retention after costs.

Question 5

Is Natco Pharma Ltd. efficient with shareholder capital?

Accepted Answer

Return on equity is 27.98%, while return on capital employed is 32.48%. A strong company generally earns good returns without taking excessive debt. Read ROE together with debt-to-equity and cash flow, because high leverage can make headline returns look better than the underlying business quality.

Question 6

Does Natco Pharma Ltd.'s valuation look expensive or reasonable?

Accepted Answer

Natco Pharma Ltd. trades at a P/E of 11.37, compared with an industry P/E of 32.10. Price-to-book is 1.88. A lower multiple is not automatically cheap, and a higher multiple is not automatically expensive; the right question is whether growth, margins, balance sheet strength, and cash generation justify the valuation.

Question 7

How strong is Natco Pharma Ltd.'s balance sheet?

Accepted Answer

Natco Pharma Ltd.'s debt-to-equity ratio is 0.05, current ratio is 3.82, and cash plus bank balance is ₹2.18K Cr. A cleaner balance sheet gives management more room during weak cycles; a stretched one makes cash flow and interest coverage more important.

Question 8

Is Natco Pharma Ltd. converting profit into cash?

Accepted Answer

Operating cash flow is ₹1.70K Cr, and free cash flow is ₹1.19K Cr. For fundamental investors, this is one of the most important checks. Profits backed by cash are generally more reliable than profits driven mainly by accounting accruals.

Question 9

How efficiently does Natco Pharma Ltd. manage working capital?

Accepted Answer

Receivable days are 102.72, inventory days are 63.10, and the cash conversion cycle is 143.17 days. Rising receivable days or a longer cash cycle can signal slower collections, even when reported revenue looks healthy.

Question 10

What does Natco Pharma Ltd.'s shareholding pattern indicate?

Accepted Answer

The latest shareholding data shows promoter holding at 49.71%, FII holding at 12.82%, and DII holding at 13.99%. Changes in institutional and promoter ownership are useful signals, but they should be read alongside earnings delivery and valuation rather than used as a standalone buy or sell trigger.

Question 11

Who are Natco Pharma Ltd.'s listed peers?

Accepted Answer

Natco Pharma Ltd. is shown alongside peers such as Cipla Ltd., Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd.. Peer comparison is useful for checking whether valuation, margins, ROE, and growth are company-specific strengths or simply sector-wide conditions.

Question 12

What should investors monitor before making a decision on Natco Pharma Ltd.?

Accepted Answer

For Natco Pharma Ltd., the most useful checklist is simple: sales growth, margin trend, ROE/ROCE, debt-to-equity, operating cash flow, free cash flow, and valuation versus peers. If these indicators improve together, the investment case becomes stronger. If they diverge, the stock needs deeper work before any decision.

Question 13

Does Natco Pharma Ltd. pay meaningful dividends?

Accepted Answer

Natco Pharma Ltd.'s current dividend yield is 0.61%. Dividend yield should be read with payout ratio and cash flow. A yield backed by free cash flow is more durable than a yield funded by balance-sheet stress or one-off income.

Question 14

How is Natco Pharma Ltd. allocating capital?

Accepted Answer

Natco Pharma Ltd.'s investing cash flow is ₹-1436.50 Cr, while financing cash flow is not available in the current dataset. This helps investors see whether cash is going into expansion, debt reduction, dividends, buybacks, or funding needs.

Question 15

Is Natco Pharma Ltd. reinvesting enough for future growth?

Accepted Answer

Capital spending and investments should be compared with revenue growth and ROCE. If Natco Pharma Ltd. can reinvest while keeping ROCE near 32.48%, growth is more valuable. If reinvestment rises while returns fall, investors should ask whether capital allocation quality is weakening.

Question 16

Is Natco Pharma Ltd.'s debt level risky?

Accepted Answer

Natco Pharma Ltd.'s debt-to-equity ratio is 0.05, and total debt is ₹260.70 Cr. Debt becomes more concerning when interest coverage weakens, cash flow turns negative, or current liabilities grow faster than current assets.

Question 17

Can Natco Pharma Ltd. service its interest cost comfortably?

Accepted Answer

Interest coverage is 96.87 times. Higher coverage gives a company more breathing room in weak markets. If coverage is not available or looks low, review finance cost trends in the P&L and cash flow from operations.

Question 18

What liquidity numbers matter most for Natco Pharma Ltd.?

Accepted Answer

The current ratio is 3.82 and quick ratio is 4.77. These ratios show short-term financial flexibility, but investors should also check receivable days and operating cash flow to understand real liquidity.

Question 19

What should investors compare in Natco Pharma Ltd.'s quarterly results?

Accepted Answer

For quarterly review, compare sales, net profit, margin, EPS, and finance cost against both the previous quarter and the same quarter last year. For Natco Pharma Ltd., the latest quarter shows sales of ₹647.30 Cr and net profit of ₹140.40 Cr.

Question 20

Is Natco Pharma Ltd.'s quarterly EPS improving?

Accepted Answer

Natco Pharma Ltd.'s latest adjusted EPS is ₹8.46. EPS should be checked with share count and one-off items. Rising EPS with stable margins is generally better quality than EPS growth driven only by lower tax or exceptional gains.

Question 21

Why should one quarter not decide the view on Natco Pharma Ltd.?

Accepted Answer

One quarter can be affected by seasonality, market volumes, input costs, or accounting timing. For Natco Pharma Ltd., the better approach is to watch a series of quarters and confirm whether sales, profit, cash flow, and working capital are telling the same story.

Question 22

How should Natco Pharma Ltd. be compared with peers?

Accepted Answer

Compare Natco Pharma Ltd. with Cipla Ltd., Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd. on P/E, revenue growth, ROE, debt, and free cash flow. A premium valuation is easier to justify when the company also has better growth, cleaner cash generation, or stronger return ratios.

Question 23

What can make Natco Pharma Ltd. deserve a higher valuation?

Accepted Answer

Natco Pharma Ltd. can deserve a higher multiple if growth is durable, ROE remains strong, free cash flow improves, and debt risk stays controlled. If those inputs weaken, a high P/E can quickly become harder to defend.

Question 24

What can make Natco Pharma Ltd. look cheap but still risky?

Accepted Answer

A lower P/E can still be risky if earnings are cyclical, cash flow is weak, debt is rising, or margins are under pressure. For Natco Pharma Ltd., valuation should be read together with sales growth of 10.77%, ROE of 27.98%, and free cash flow of ₹1.19K Cr.

Question 25

Is promoter pledging a concern for Natco Pharma Ltd.?

Accepted Answer

Promoter pledge is 0.00%. High pledge can increase risk during market corrections. A low or zero pledge is cleaner, but it still needs to be viewed with promoter holding trend and business performance.

Question 26

Are institutions increasing or reducing exposure to Natco Pharma Ltd.?

Accepted Answer

Latest FII holding is 12.82% and DII holding is 13.99%. Institutional movement can show market confidence, but it is best used as confirmation after checking earnings, valuation, and cash flow.

Question 27

What governance signals should be watched in Natco Pharma Ltd.?

Accepted Answer

Watch promoter holding, pledge, related-party disclosures, auditor remarks, debt changes, and cash conversion. Governance risk often shows up first in balance-sheet quality and cash flow, not only in headline profit.

Question 28

Is Natco Pharma Ltd. better suited for growth or value investors?

Accepted Answer

Natco Pharma Ltd. can be assessed by both styles. Growth investors should focus on sales growth, quarterly momentum, and reinvestment quality. Value investors should focus on valuation versus peers, cash flow, debt, and margin durability.

Question 29

What are the main risks investors should track for Natco Pharma Ltd.?

Accepted Answer

The main risks to track are slowing sales growth, margin compression, weak free cash flow, rising debt, higher receivable days, and expensive valuation. These risks matter more when several appear together rather than in isolation.

Question 30

What is a practical checklist before buying Natco Pharma Ltd.?

Accepted Answer

Before taking a view on Natco Pharma Ltd., check five things: revenue growth, profit margin, ROE/ROCE, free cash flow, and valuation versus peers. If the numbers disagree, wait for more evidence instead of forcing a conclusion from one metric.

Natco Pharma Ltd. Financial Terminal

Analyst FAQ

Key facts used in answers

Market Cap

P/E Ratio

ROE

Dividend Yield

6PROS

1CONS

3Business Snapshot

3Profitability And Valuation

3Balance Sheet And Cash Flow

3Ownership And Investor Checks

3Dividends And Capital Allocation

3Debt Risk And Financial Safety

3Quarterly Trend Checks

3Peer Comparison And Valuation

3Governance And Ownership Quality

3Investor Strategy And Risk Checklist

Important Investment Disclaimer